Myelodysplasia Syndrome, Clonal Hematopoiesis and Cardiovascular Disease
- Author(s)
- Veiga, CB; Lawrence, EM; Murphy, AJ; Herold, MJ; Dragoljevic, D;
- Details
- Publication Year 2021-04-19,Volume 13,Issue #8,Page 1968
- Journal Title
- Cancers
- Abstract
- The development of myelodysplasia syndromes (MDS) is multiphasic and can be driven by a plethora of genetic mutations and/or abnormalities. MDS is characterized by a hematopoietic differentiation block, evidenced by increased immature hematopoietic cells, termed blast cells and decreased mature circulating leukocytes in at least one lineage (i.e., cytopenia). Clonal hematopoiesis of indeterminate potential (CHIP) is a recently described phenomenon preceding MDS development that is driven by somatic mutations in hemopoietic stem cells (HSCs). These mutant HSCs have a competitive advantage over healthy cells, resulting in an expansion of these clonal mutated leukocytes. In this review, we discuss the multiphasic development of MDS, the common mutations found in both MDS and CHIP, how a loss-of-function in these CHIP-related genes can alter HSC function and leukocyte development and the potential disease outcomes that can occur with dysfunctional HSCs. In particular, we discuss the novel connections between MDS development and cardiovascular disease.
- Publisher
- MDPI
- Keywords
- Asxl1; Dnmt3a; Jak2; P53; Tet2; cardiovascular disease; clonal hematopoiesis and indeterminate potential (CHIP); hematopoietic stem cell (HSC); myelodysplasia syndrome
- Research Division(s)
- Blood Cells And Blood Cancer
- PubMed ID
- 33921778
- Publisher's Version
- https://doi.org/10.3390/cancers13081968
- Open Access at Publisher's Site
https://doi.org/10.3390/cancers13081968- NHMRC Grants
- NHMRC/1156095,
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2021-05-11 04:12:19
Last Modified: 2021-05-17 11:35:17